



09-30-02

#4

03C2

ATTORNEY DOCKET NO. DASL005.00US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Philippe Pouletty *et al*

Serial No.: 10/057,791

Filed: January 23, 2002

For: New amphetamine derivatives, antibodies  
against them and pharmaceutical compositions  
containing them

) Examiner: Not yet assigned

) Art Unit: Not yet assigned

) **TRANSMITTAL SECOND**  
) **INFORMATION DISCLOSURE**  
) **STATEMENT**

**BOX DD**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Transmitted herewith is:

- [X] A Second Information Disclosure Statement.
- [X] A Form PTO-1449.
- [X] Copies of references A4 - A7, C1 and D7 as listed on Form PTO-1449 attached hereto, and references A1 - A3, D1 and D4 as listed on Form PTO-1449 filed April 11, 2002.

**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" Label No.: EV214276947US

Date of Deposit: September 26 2002

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX DD, Commissioner for Patents, Washington, D.C., 20231.

Karen Patchen  
(Signature)

Karen Patchen  
(Printed Name)

**PATENT**

**ATTORNEY DOCKET NO. DASI.005.00US**

- ☒ Return postcard (postage prepaid).
1. ☒ This Information Disclosure Statement is filed before the later of:
- ☐ three months from the filing date of this national application;
  - ☐ three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or
  - ☒ the mailing date of a first office action on the merits.
- ☒ In accordance with 37 C.F.R. § 1.97(b), no fee is required.
2. ☐ This Information Disclosure Statement is filed after the events noted in paragraph 2, but before either:
- (1) a final action under 37 C.F.R. § 1.113; or
  - (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- ☐ In accordance with 37 C.F.R. § 1.97(c) also enclosed is:
- ☐ a fee under 37 C.F.R. § 1.17(p) in the amount of \$240; or
  - ☐ a certification as stated below.
3. ☐ This Information Disclosure statement is filed before the payment of the issue fee, but after either:
- (1) a final action under 37 C.F.R. § 1.113; or
  - (2) a Notice of Allowance under 37 C.F.R. § 1.311.
- ☐ In accordance with 37 C.F.R. § 1.97(d) also enclosed is:
- (1) A certification, as stated below;
  - (2) A Petition requesting consideration of the Information Disclosure Statement; and
  - (3) The petition fee set forth in 37 C.F.R. § 1.17(i)(1) in the amount of \$130.

Certification

The undersigned also states:

- ☐ Each item of information contained in the Information Disclosure Statement cited herein was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of this Information Disclosure Statement.

The fees indicated above are:

**TOTAL FEES: \$**

- ☐ A check including the amount of the above-indicated TOTAL FEES is attached.
- ☐ Please charge Deposit Account No. 18-0020 in the amount of: \$ \_\_\_\_\_.
- ☐ A check in the amount of \$ \_\_\_\_\_ is attached.
- ☒ No fee is required.
- ☒ The Commissioner is hereby authorized to charge any underpayment of the following fees associated with this communication, including any necessary fees for extension of time, or credit any overpayment to Deposit Account No. 18-0020.
- ☒ Any filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.
- ☒ A duplicate copy of this sheet is attached for accounting purposes.

PATENT

ATTORNEY DOCKET NO. DASI.005.00US

Respectfully submitted,

Dated: September 16, 2012



Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C.  
PO Box 1898  
Monterey, CA 93942-1898  
Phone: (831) 648-3090  
Facsimile: (831) 242-0137

BRV/ma



ATTORNEY DOCKET NO. DASL005.00US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Philippe Pouletty <i>et al</i>	) Examiner: Not yet assigned
	)
Serial No.: 10/057,791	) Art Unit: Not yet assigned
	)
Filed: January 23, 2002	)
	)
For: New amphetamine derivatives, antibodies	) <u>SECOND INFORMATION</u>
against them and pharmaceutical compositions	) <u>DISCLOSURE STATEMENT</u>
containing them	)

**BOX DD**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Second Information Disclosure Statement is hereby submitted in accordance with 37 CFR 1.98 and pursuant to Applicant's continuing duty under 37 CFR 1.56 to bring any information which may be material to patentability of this application to the Examiner's attention.

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No.: EV214276947 US

Date of Deposit: September 26 2002

I hereby certify under 37 C.F.R. 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX DD, Commissioner for Patents, Washington, D.C., 20231.

Karen Patchen  
(Signature)

Karen Patchen  
(Printed Name)

**PATENT**


**ATTORNEY DOCKET NO. DASL.005.00US**

Applicant makes no representation that a complete search has been conducted by the Applicant, or that there is not possibly more relevant art. Applicant also makes no representation that the information submitted herewith is in fact material.

The subject application is believed patentable over any of the above references.

Respectfully submitted,

Dated: September 26, 2002

  
\_\_\_\_\_  
Barbara Rae-Venter, Ph.D.  
Reg. No. 32,750

Rae-Venter Law Group, P.C.  
PO Box 1898  
Monterey, CA 93942-1898  
Phone: (831) 648-3090  
Facsimile: (831) 242-0137

BRV/ma

PATENT

DOCKET NO DASI.005.00US

COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231FORM PTO-1449 (Modified)  
LIST OF PATENTS AND PUBLICATIONS  
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)  
Sheet 1 of 1In re the application of: Pouletty *et al.*]  
]  
]  
]

Art Unit: Not yet assigned

Serial No. 10/057,791

Examiner: Not yet assigned

Filed: January 23, 2002

## U.S. PATENT DOCUMENTS

Ref.	Examiner's	Document			Class/	Filing
<u>Desig.</u>	<u>Initials</u>	<u>Number</u>	<u>Date</u>	<u>Name</u>	<u>Subclass</u>	<u>Date</u>
A4		5,840,307	11/24/98	Swain, et al.		6/1/95
A5		5,760,184	6/2/98	Swain, et al.		11/28/95
A6		5,876,727	3/2/99	Swain, et al.		9/30/96
A7		6,054,127	4/25/00	Swain, et al.		6/27/97

## PENDING U.S. PATENT DOCUMENTS

Ref.	Examiner's				
<u>Desig.</u>	<u>Initials</u>	<u>Document Number</u>	<u>Name</u>	<u>Filing Date</u>	

## FOREIGN PATENT DOCUMENTS

Ref.	Examiner's	Document			Class/	
<u>Desig.</u>	<u>Initials</u>	<u>Number</u>	<u>Date</u>	<u>Country</u>	<u>Subclass</u>	<u>Filing Date</u>
C1		WO 01/81424 A1	11/01/2001	PCT		04/20/01

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref.	Examiner's		
<u>Desig.</u>	<u>Initials</u>		
D7		Choi, J, et al., J. Immunoassay & Immunochemistry. 2002. 23(1), 69-83.	

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.